MX2023004108A - Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer. - Google Patents

Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer.

Info

Publication number
MX2023004108A
MX2023004108A MX2023004108A MX2023004108A MX2023004108A MX 2023004108 A MX2023004108 A MX 2023004108A MX 2023004108 A MX2023004108 A MX 2023004108A MX 2023004108 A MX2023004108 A MX 2023004108A MX 2023004108 A MX2023004108 A MX 2023004108A
Authority
MX
Mexico
Prior art keywords
quinazolin
amine
group
cancer
thieno
Prior art date
Application number
MX2023004108A
Other languages
Spanish (es)
Inventor
Thomas Radimerski
Stefan Reinelt
Florian Richalet
Sven Weiler
Bérangère Gaucher
Andrea Aloia
Original Assignee
Redona Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redona Therapeutics Inc filed Critical Redona Therapeutics Inc
Publication of MX2023004108A publication Critical patent/MX2023004108A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention provides compounds of formula (IA) and compounds of formula (IB) and pharmaceutically acceptable salts thereof; wherein A is selected from group (A1) and group (A2): wherein #1 is attached to the carbon atom forming the oxime moiety and wherein group (A1) is optionally substituted by one or two R10 and group (A2) is optionally substituted by one R10, and wherein R1, X, R2 and R10 are as defined in the claims, as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.
MX2023004108A 2020-10-08 2021-10-07 Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer. MX2023004108A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20200850 2020-10-08
EP20213590 2020-12-11
EP21165054 2021-03-25
PCT/EP2021/077757 WO2022074143A1 (en) 2020-10-08 2021-10-07 Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2023004108A true MX2023004108A (en) 2023-06-28

Family

ID=78080359

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004108A MX2023004108A (en) 2020-10-08 2021-10-07 Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer.

Country Status (10)

Country Link
US (1) US20230365509A1 (en)
EP (1) EP4225740A1 (en)
JP (1) JP2023544847A (en)
KR (1) KR20230104163A (en)
AU (1) AU2021356130A1 (en)
CA (1) CA3195150A1 (en)
IL (1) IL301964A (en)
MX (1) MX2023004108A (en)
TW (1) TW202229245A (en)
WO (1) WO2022074143A1 (en)

Also Published As

Publication number Publication date
AU2021356130A9 (en) 2024-09-26
IL301964A (en) 2023-06-01
TW202229245A (en) 2022-08-01
CA3195150A1 (en) 2022-04-14
US20230365509A1 (en) 2023-11-16
EP4225740A1 (en) 2023-08-16
AU2021356130A1 (en) 2023-05-18
WO2022074143A1 (en) 2022-04-14
KR20230104163A (en) 2023-07-07
JP2023544847A (en) 2023-10-25

Similar Documents

Publication Publication Date Title
MXPA05011670A (en) Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders.
MX2022015703A (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders.
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
PL1678166T3 (en) Protein kinase inhibitors
NZ543897A (en) Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
BG106480A (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
MX2009008338A (en) Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions.
MX2021009743A (en) Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders.
MX2009003874A (en) Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents.
TW200716547A (en) Piperidin-4-yl-amide derivatives
IL138079A0 (en) 5-aminoindeno (1,2-c) pyrazol-4-ones as anti-cancer and anti-proliferative agents
WO2002044174A3 (en) 3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors
MX2007001267A (en) 2, 8-disubstituted naphthyridine derivatives.
ES2187261A1 (en) Ether and amide compounds and preparation of thereof as antidiadetics.
WO2001012169A3 (en) Method of cancer treatment
CR20210602A (en) Pyrrolidine compounds
MX2019008116A (en) PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED 5-AMINO-6H-TH IAZOLO[4,5-d]PYRIMIDINE-2,7-DIONE COMPOUNDS.
CR20210014A (en) Pyrrolo[1,2-b] pyridazine derivatives
MX2023004108A (en) Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer.
WO2009008345A1 (en) Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound
ZA200703275B (en) 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinollnecarbonitriles for the treatment of ischemic Injury
WO2009019721A3 (en) Quercetin derivatives as anti-cancer agents
WO2009057795A8 (en) Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
MX2022001412A (en) 7,8-DIHYDRO-4H-PYRAZOLO[4,3-c]AZEPINE-6-ONE COMPOUNDS.
CA3047992A1 (en) Azaindenoisoquinoline compounds and uses thereof